Loading
A phase 3 trial of Technetium-99m tilmanocept in Breast cancer and Melanoma, run by Navidea Biopharmaceuticals, completed.
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes is a phase 3 interventional study registered as NCT01106040 by Navidea Biopharmaceuticals, with 163 participants recorded, started 2010-06 and reaching its primary completion in 2011-04. Interventions recorded: Lymphoseek. Conditions recorded: Breast Cancer, Melanoma.
Linked to the drug Technetium-99m tilmanocept because the registry names it among its interventions and Breast cancer and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
163 enrolled.
95% CI 0.9840 to 1.0000; Figures from the ClinicalTrials.gov results section (first posted 2013-06-03), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Concordance of Blue Dye and Lymphoseekprimary | Intent-To-Treat | 133 | 1 proportion of lymph nodes | - | - | link |
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept, Breast cancer (all types), Melanoma and the tag pipeline.
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept and the tag pipeline.
Shares Technetium-99m tilmanocept and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.